Joel Morris

3.0k total citations · 2 hit papers
31 papers, 1.9k citations indexed

About

Joel Morris is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Joel Morris has authored 31 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 14 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Joel Morris's work include Lung Cancer Treatments and Mutations (5 papers), DNA Repair Mechanisms (4 papers) and Protein Degradation and Inhibitors (4 papers). Joel Morris is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), DNA Repair Mechanisms (4 papers) and Protein Degradation and Inhibitors (4 papers). Joel Morris collaborates with scholars based in United States, Malaysia and Japan. Joel Morris's co-authors include James H. Doroshow, Yves Pommier, Beverly A. Teicher, Shunichi Takeda, Yiping Zhang, Jiuping Ji, Junko Murai, Sudhir Varma, Kurt W. Kohn and Margot Sunshine and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Joel Morris

25 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set

2012 635 citations William C. Reinhold, Margot Sunshine et al. Cancer Research profile →
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

2013 592 citations Junko Murai, Shar-yin N. Huang et al. Molecular Cancer Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joel Morris United States	12	1.4k	1.2k	373	323	174	31	1.9k
Emma Dean United Kingdom	29	1.8k 1.3×	1.4k 1.3×	390 1.0×	436 1.3×	256 1.5×	132	2.7k
T. Khanh United States	26	1.6k 1.2×	991 0.9×	462 1.2×	473 1.5×	238 1.4×	57	2.5k
Patrick G. Pilié United States	13	1.1k 0.8×	1.1k 0.9×	407 1.1×	342 1.1×	227 1.3×	43	1.8k
Meilan Liu United States	18	995 0.7×	575 0.5×	292 0.8×	427 1.3×	195 1.1×	46	1.6k
Evelyn McKeegan United States	19	1.3k 1.0×	771 0.7×	288 0.8×	234 0.7×	238 1.4×	42	2.1k
Janneke E. Jaspers Netherlands	15	1.4k 1.0×	1.5k 1.3×	226 0.6×	284 0.9×	208 1.2×	17	2.0k
Bose Kochupurakkal United States	16	1.0k 0.7×	810 0.7×	169 0.5×	183 0.6×	117 0.7×	44	1.4k
Alexander R. Shoemaker United States	19	2.2k 1.6×	906 0.8×	164 0.4×	311 1.0×	336 1.9×	22	3.0k
Amir Sonnenblick Israel	22	743 0.5×	885 0.8×	212 0.6×	450 1.4×	234 1.3×	92	1.6k
Aaron Cranston United Kingdom	18	1.9k 1.4×	1.8k 1.6×	155 0.4×	319 1.0×	343 2.0×	42	2.8k

Countries citing papers authored by Joel Morris

Since Specialization

Citations

This map shows the geographic impact of Joel Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Morris more than expected).

Fields of papers citing papers by Joel Morris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Morris. The network helps show where Joel Morris may publish in the future.

Co-authorship network of co-authors of Joel Morris

This figure shows the co-authorship network connecting the top 25 collaborators of Joel Morris. A scholar is included among the top collaborators of Joel Morris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel Morris. Joel Morris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dexheimer, Thomas S., Nathan P. Coussens, Raymond G. Fox, et al.. (2025). RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types. Cancer Research Communications. 5(10). 1779–1795.

Dexheimer, Thomas S., Nathan P. Coussens, Thomas Silvers, et al.. (2025). Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids. SLAS DISCOVERY. 32. 100222–100222. 2 indexed citations

Kunkel, Mark W., Nathan P. Coussens, Joel Morris, et al.. (2024). HTS384 NCI60: The Next Phase of the NCI60 Screen. Cancer Research. 84(15). 2403–2416. 11 indexed citations

Dexheimer, Thomas S., Nathan P. Coussens, Eric A. Jones, et al.. (2024). Combination screen in multi-cell type tumor spheroids reveals interaction between aryl hydrocarbon receptor antagonists and E1 ubiquitin-activating enzyme inhibitor. SLAS DISCOVERY. 29(7). 100186–100186. 3 indexed citations

Dexheimer, Thomas S., Nathan P. Coussens, John Wright, et al.. (2023). Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs. Cancer Research Communications. 3(8). 1648–1661. 6 indexed citations

Morris, Joel, Donn G. Wishka, Omar D. Lopez, et al.. (2021). F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd. Molecular Cancer Therapeutics. 20(4). 625–631. 7 indexed citations

Wishka, Donn G., et al.. (2020). The development of β-selective glycosylation reactions with benzyl substituted 2-deoxy-1,4-dithio-D- erythro -pentofuranosides: enabling practical multi-gram syntheses of 4'-Thio-2'-deoxycytidine (T-dCyd) and 5-aza-4’-thio-2’-deoxycytidine (aza-T-dCyd) to support clinical development. Nucleosides Nucleotides & Nucleic Acids. 40(1). 68–95. 4 indexed citations

Teicher, Beverly A., Richard B. Lock, Kathryn Evans, et al.. (2019). Abstract 3839: Comparison of thio-deoxy-cytidine (TdCyd) and aza-thio-deoxy-cytidine (Aza-TdCyd) in solid and liquid tumor cell lines and PPTC pediatric xenografts. Cancer Research. 79(13_Supplement). 3839–3839. 1 indexed citations

Polley, Eric C., Mark W. Kunkel, David M. Evans, et al.. (2016). Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression. JNCI Journal of the National Cancer Institute. 108(10). djw122–djw122. 106 indexed citations

10.

Teicher, Beverly A., Eric C. Polley, Mark W. Kunkel, et al.. (2015). Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression. Molecular Cancer Therapeutics. 14(11). 2452–2462. 55 indexed citations

11.

Kaur, Gurmeet, Russell Reinhart, Anne Monks, et al.. (2015). Bromodomain and hedgehog pathway targets in small cell lung cancer. Cancer Letters. 371(2). 225–239. 40 indexed citations

12.

Eldridge, Sandy, Joseph M. Covey, Joel Morris, et al.. (2014). Characterization of acute biliary hyperplasia in Fisher 344 Rats administered the Indole-3-Carbinol Analog, NSC-743380. Toxicology and Applied Pharmacology. 281(3). 303–309. 5 indexed citations

13.

Murai, Junko, Yiping Zhang, Joel Morris, et al.. (2014). Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition. Journal of Pharmacology and Experimental Therapeutics. 349(3). 408–416. 206 indexed citations

14.

Reinhold, William C., Sudhir Varma, Fabrício G. Sousa, et al.. (2014). NCI-60 Whole Exome Sequencing and Pharmacological CellMiner Analyses. PLoS ONE. 9(7). e101670–e101670. 35 indexed citations

15.

Morris, Joel, Mark W. Kunkel, Eric C. Polley, et al.. (2014). Abstract 5475: Interrogation of NCI-60 patterns of growth inhibition in conjunction with investigational oncology agents kinase profiling for the elucidation of mechanistic targets. Cancer Research. 74(19_Supplement). 5475–5475.

16.

Jossé, Rozenn, Scott E. Martin, Rajarshi Guha, et al.. (2014). ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses. Cancer Research. 74(23). 6968–6979. 121 indexed citations

17.

Murai, Junko, Shar-yin N. Huang, Amèlie Renaud, et al.. (2013). Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib. Molecular Cancer Therapeutics. 13(2). 433–443. 592 indexed citations breakdown →

18.

Murai, Junko, Shar-yin N. Huang, Amèlie Renaud, et al.. (2013). Abstract A257: Stereospecific trapping of PARP-DNA complexes by BMN 673 and comparison with olaparib and rucaparib.. Molecular Cancer Therapeutics. 12(11_Supplement). A257–A257. 1 indexed citations

19.

Morris, Joel, et al.. (2004). Conjunctival involvement with T-cell prolymphocytic leukemia: report of a case and review of the literature. Survey of Ophthalmology. 49(5). 525–536. 7 indexed citations

20.

Grout, B.W.W., et al.. (1990). Cryopreservation and the maintenance of cell lines. Trends in biotechnology. 8(10). 293–297. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact